These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18813140)

  • 1. Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease.
    McDowell R; Li JS; Benjamin DK; Morgan C; Becker A; Kishnani PS; Kanter RJ
    Genet Med; 2008 Oct; 10(10):758-62. PubMed ID: 18813140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease.
    Cook AL; Kishnani PS; Carboni MP; Kanter RJ; Chen YT; Ansong AK; Kravitz RM; Rice H; Li JS
    Genet Med; 2006 May; 8(5):313-7. PubMed ID: 16702882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease.
    Levine JC; Kishnani PS; Chen YT; Herlong JR; Li JS
    Pediatr Cardiol; 2008 Nov; 29(6):1033-42. PubMed ID: 18661169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrocardiographic response to enzyme replacement therapy for Pompe disease.
    Ansong AK; Li JS; Nozik-Grayck E; Ing R; Kravitz RM; Idriss SF; Kanter RJ; Rice H; Chen YT; Kishnani PS
    Genet Med; 2006 May; 8(5):297-301. PubMed ID: 16702879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case series.
    Wang LY; Ross AK; Li JS; Dearmey SM; Mackey JF; Worden M; Corzo D; Morgan C; Kishnani PS
    Paediatr Anaesth; 2007 Aug; 17(8):738-48. PubMed ID: 17596219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy.
    Barker PC; Pasquali SK; Darty S; Ing RJ; Li JS; Kim RJ; DeArmey S; Kishnani PS; Campbell MJ
    Mol Genet Metab; 2010 Dec; 101(4):332-7. PubMed ID: 20875764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy.
    Forsha D; Li JS; Smith PB; van der Ploeg AT; Kishnani P; Pasquali SK;
    Genet Med; 2011 Jul; 13(7):625-31. PubMed ID: 21543987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy for infantile-onset Pompe disease.
    Chen M; Zhang L; Quan S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011539. PubMed ID: 29155436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of cardiac dysfunction after enzyme replacement in patients with infantile-onset Pompe disease.
    Chen LR; Chen CA; Chiu SN; Chien YH; Lee NC; Lin MT; Hwu WL; Wang JK; Wu MH
    J Pediatr; 2009 Aug; 155(2):271-5.e2. PubMed ID: 19486996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
    Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
    Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report.
    Del Rizzo M; Fanin M; Cerutti A; Cazzorla C; Milanesi O; Nascimbeni AC; Angelini C; Giordano L; Bordugo A; Burlina AB
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S389-93. PubMed ID: 20830524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.
    Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T
    Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When should we start enzyme replacement therapy for infantile Pompe disease with severe cardiomyopathy?
    Bonilla-Palomas JL; Gámez-López AL; Tejero-Hernández MA; Tejero-Mateo I; López-López J
    Rev Esp Cardiol (Engl Ed); 2012 Jan; 65(1):100-2. PubMed ID: 21715078
    [No Abstract]   [Full Text] [Related]  

  • 14. [Enzyme replacement therapy in a boy with infantile Pompe disease: cardiac follow-up].
    Bonnefoy R; Labarthe F; Paoli F; Chantreuil J; Barthez MA; Froissart R; Poinsot J; Chantepie A
    Arch Pediatr; 2008 Dec; 15(12):1760-4. PubMed ID: 18995995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.
    Klinge L; Straub V; Neudorf U; Voit T
    Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.
    Parini R; De Lorenzo P; Dardis A; Burlina A; Cassio A; Cavarzere P; Concolino D; Della Casa R; Deodato F; Donati MA; Fiumara A; Gasperini S; Menni F; Pagliardini V; Sacchini M; Spada M; Taurisano R; Valsecchi MG; Di Rocco M; Bembi B
    Orphanet J Rare Dis; 2018 Feb; 13(1):32. PubMed ID: 29422078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohort.
    Byrne BJ; Colan SD; Kishnani PS; Foster MC; Sparks SE; Gibson JB; An Haack K; Stockton DW; Peña LDM; Hahn SH; Johnson J; Tanpaiboon PX; Leslie ND; Kronn D; Hillman RE; Wang RY;
    Cardiol Young; 2022 Mar; 32(3):364-373. PubMed ID: 34420548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular and histologic findings in a series of children with infantile pompe disease treated with enzyme replacement therapy.
    Prakalapakorn SG; Proia AD; Yanovitch TL; DeArmey S; Mendelsohn NJ; Aleck KA; Kishnani PS
    J Pediatr Ophthalmol Strabismus; 2014; 51(6):355-62. PubMed ID: 25139343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease.
    Kanters TA; Hoogenboom-Plug I; Rutten-Van Mölken MP; Redekop WK; van der Ploeg AT; Hakkaart L
    Orphanet J Rare Dis; 2014 May; 9():75. PubMed ID: 24884717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study.
    van Gelder CM; Poelman E; Plug I; Hoogeveen-Westerveld M; van der Beek NAME; Reuser AJJ; van der Ploeg AT
    J Inherit Metab Dis; 2016 May; 39(3):383-390. PubMed ID: 26768149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.